eligibility_summary
Adults (≥18) with WHO grade I–IIIA follicular lymphoma, stage IA/IIA or IE, non‑bulky (<7 cm), PET/CT-staged, no prior therapy (steroids allowed), FLIPI<2 and FLIPI2≤2, ECOG≤2, negative bone marrow, measurable node ≥2 cm, adequate renal/hepatic function, central BCL2/IGH and t(14,18) testing, consent, ≥3‑mo life expectancy, contraception. Exclude grade IIIb, stage>II/B symptoms/bulky or multifield, cutaneous FL, HIV, active HBV/HCV, CNS disease, serious comorbidity/other cancers, pregnancy, other trials.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase III trial in early-stage (I–II) follicular lymphoma: involved-site radiotherapy (ISRT) 24 Gy alone vs ISRT 24 Gy followed by obinutuzumab. Obinutuzumab is a type II, glycoengineered, humanized anti-CD20 monoclonal antibody (1000 mg weekly ×4 then every 3 weeks ×4) that binds CD20 on B cells to induce direct cell death and enhance antibody-dependent cellular cytotoxicity and phagocytosis, depleting malignant CD20+ B cells. Radiotherapy induces localized DNA double-strand breaks leading to apoptosis/mitotic death and can modulate anti-tumor immunity. Targets: CD20+ germinal center B-cell lymphoma cells, pathways: Fcγ-mediated effector functions and DNA-damage/apoptosis pathways.